Innate Pharma S.A. (IPHA) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 22.1% versus a loss of 47.8%. Over five years, VYGR leads with a -39.8% price change compared with -74.1% for IPHA. Innate Pharma S.A. is the larger company by market cap ($169.8 million vs $152.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | VYGR |
|---|---|---|
| Share price | $1.52 | $2.47 |
| Market cap | $169.78M | $152.20M |
| 1-day change | -4.40% | +0.41% |
| YTD return | -13.14% | -37.15% |
| 1-year return | -22.05% | -47.78% |
| 5-year return | -74.11% | -39.76% |
| EPS (TTM) | $-0.59 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $5.55 |
| 52-week low | $1.17 | $2.39 |
| Distance from 52-week high | -43.91% | -55.50% |
| Average volume | 156.58K | 563.34K |
| Shares outstanding | 111.70M | 61.62M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed VYGR by 25.7 percentage points over the past year.
IPHA vs VYGR FAQ
Which is bigger, Innate Pharma S.A. or Voyager Therapeutics?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $169.78M compared with $152.20M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, IPHA or VYGR?
IPHA returned -22.05% over the past 12 months, compared with -47.78% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.